Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukemia/lymphotropic virus type 1 (HTLV-1) infection in vitro

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 6, 2003, Pages 1327-1330

  Macchi, Beatrice ^a   Balestrieri, Emanuela ^b   Mastino, Antonio ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antiviral; HTLV 1; In vitro

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DNA INTEGRATION; DOSE RESPONSE; DRUG EFFICACY; GENOTOXICITY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IN VITRO STUDY; NONHUMAN; RNA VIRUS INFECTION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS TRANSFORMATION; VIRUS TRANSMISSION;

ANIMALS; ANTI-RETROVIRAL AGENTS; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LAMIVUDINE; NUCLEOSIDES; ZIDOVUDINE;

EID: 0038309409     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg240     Document Type: Article

References (18)

1. Edlich, R. F., Arnette, J. A. & Williams, F. M. (2000). Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). Journal of Emergency Medicine 18, 109-19.
2. Yao, J. & Wigdahl, B. (2000). Human T cell lymphotropic virus type I genomic expression and impact on intracellular signaling pathways during neurodegenerative disease and leukemia. Frontiers in Bioscience 5, D138-68.
3. Franchini, G. (1995). Molecular mechanism of human T cell leukaemia/lymphotropic virus type 1 infection. Blood 86, 3619-39.
4. Yamada, Y., Tomonaga, M., Fukuda, H., Hanada, S., Utsunomiya, A., Ta, M. et al. (2001). A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study 9303. British Journal of Haematology 113, 375-82.
5. Gill, S. P., Harrington, W. J. R., Kaplan, M. H., Ribeiro, R. C., Bennet, J. M., Liebman, H. A. et al. (1995). Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. New England Journal of Medicine 332, 1744-8.
6. Hermine, O., Bouscary, D., Gessain, A., Turlure, P., Leblond, V., Franck, N. et al. (1995). Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. New England Journal of Medicine 332, 1749-51.
7. Machuca, A. & Soriano, V. (2000). In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs. Journal of Acquired Immunodeficiency Syndromes 24, 189-93.
8. Taylor, G. P., Hall, S. E., Navarrete, S., Michie, C. A., Davis, R., Witkover, A. D. et al. (1999). Effect of lamivudine on human T-cell leukaemia virus type I (HTLV-1) DNA copy number, T-cell phenotype, and anti-Tax cytotoxic T-cell frequency in patients with HTLV-1 associated myelopathy. Journal of Virology 73, 10289-95.
9. Macchi, B., Faraoni, I., Mastino, A., D'Onofrio, C., Romeo, G. & Bonmassar, E. (1993). Protective effect of beta interferon on human T cell leukaemia virus type I infection of CD4+ T cells isolated from human cord blood. Cancer Immunology Immunotherapy 37, 97-104.
10. Darwiche, N., El-Sabban, M., Nasr, R., AI-Hashimi, S., Hermine, O., de The, H. et al. (2001). Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells. Hematology Journal 2, 127-35.
11. Miyoshi, I., Kubonishi, I., Yoshimoto, S., Akagi, T., Ohtsuki, Y., Shirashi, Y. et al. (1981). Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic cells. Nature 294, 770-1.
12. Macchi, B., Popovic, M., Allavena, P., Ortaldo, J., Rossi, P., Gallo, R. C. et al. (1987). In vitro susceptibility of different human T-cell subpopulations and resistance of large granular lymphocytes to HTLV-1 infection. International Journal of Cancer 40, 1-6.
13. Matsushita, S., Mitsuya, H., Reitz, M. S. & Broder, S. (1987). Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. Journal of Clinical Investigation 80, 394-400.
14. Macchi, B., Faraoni, I., Zhang, J., Grelli, S., Favalli, C., Mastino, A. et al. (1997). AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mono-nuclear cells in vitro. Journal of General Virology 78, 1007-16.
15. Sussman, H. E., Olivero, O. A., Meng, Q., Pietras, S. M., Poirier, M. C., O'Neill, J. P. et al. (1999). Genotoxicity of 3′-azido-3′-deoxythymidine in the human lymphoblastoid cell line, TK6: relationship between DNA incorporation, mutant frequency, and spectrum of deletion mutation in HPRT. Mutation Research 429, 249-59.
16. Zhang, J., Balestrieri, E., Grelli, S., Matteucci, C., Pagnini, V., D'Agostini, C. et al. (2001). Efficacy of 3′-azido 3′ deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells. Virus Research 78, 67-78.
17. Balestrieri, E., Forte, G., Matteucci, C., Mastino, A. & Macchi, B. (2002). Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrobial Agents and Chemotherapy 46, 3080-3.
18. Garcia-Lerma, J. G., Nidtha, S. & Heneine, W. (2001). Susceptibility of human T cell leukemia virus type 1 to reverse transcriptase inhibitors: evidence for resistance to lamivudine. Journal of Infectious Diseases 184, 507-10.